M. Mauletbayev

The Use of Selpercatinib in Recurrent Medullary Thyroid Carcinoma with the RET p.C630R Mutation: A Clinical Case

Medullary thyroid carcinoma (MTC) is a rare malignant tumor arising from parafollicular C cells and accounts for 1–5% of all thyroid cancers. Somatic RET mutations occur in 40–50% of sporadic cases and represent targets for selective RET inhibitors. Selpercatinib (RETEVMO, Eli Lilly), approved by the FDA in 2020 and th...